Why use Blephasteam® ?

Innovative medical device Class IIa

Blephasteam® is an innovative and patented device. It is aligned device with experts guidelines.
Blesphasteam® uses proven heat and humidity therapy.
Daily sessions of 10 minutes are enough to regain ocular comfort.

For all the family

Blephasteam® is intended for the eye comfort of the whole family (adults & children from 3 years old) thanks to a removable & fully adjustable water carrier / face seal*.

*Children’s water carrier can be ordered separately


High Prevalence of MGD Among the general population

What is Meibomian Gland Dysfunction?

Meibomian Gland Dysfunction (MGD) is a chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative or quantitative changes in the glandular secretion(1).

How many people have Meibomian Gland Dysfunction ?

54%

86%

of patients with dry eye have MGD signs(3)


What are the symptoms of MGD? (1)

Major MGD risk factors

• Aging : older patients have an increased risk of developing MGD (4 /5)
• Chronic anterior and posterior blepharitis (5)
• Contact lens wear (5)
• Decreased blinking rate : in people who stare at a computer screen or use it frequently. (6)

Eyelid hygiene is the cornerstone of the treatment of MGD & associated diseases (7)

Eyelid warming is the first step in eyelid hygiene(7).

Blephasteam® the premium eyelid warming device for the management of Meibomian Gland Dysfunction (MGD) and associated diseases such as dry eye syndrome, chalazion, blepharitis or ocular rosacea. (12) 


How does Blephasteam® work? Watch our video.

References :
1. Nichols KK, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1922-9
2. Doan S, et al. Eyelid Disorders in Ophthalmology Practice: Results from a Large International Epidemiological Study in Eleven Countries. Ophthalmol Ther. 2020 Sep;9(3):597-608
3. Lemp MA, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012 May;31(5):472-8
4. Hom MM, et al. Prevalence of Meibomian gland dysfunction. Optom Vis Sci. 1990 Sep;67(9):710-2
5. Schaumberg DA, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1994-2005
6. Wan T, et al. Incomplete Blinking May Attribute to the Development of Meibomian Gland Dysfunction. Curr Eye Res. 2016;41(2):179-85
7. Geerling G, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):2050-64
8. Benitez-Del-Castillo JM. How to promote and preserve eyelid health. Clin Ophthalmol. 2012;6:1689-98
9. Geerling G, et al. Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting. Ocul Surf. 2017 Apr;15(2):179-192
10. Pult H, et al. A comparison of an eyelid-warming device to traditional compress therapy. Optom Vis Sci. 2012 Jul;89(7)
11. Kenrick CJ, et al. The Limitation of Applying Heat to the External Lid Surface: A Case of Recalcitrant Meibomian Gland Dysfunction. Case Rep Ophthalmol. 2017 Jan 16;8(1):7-12
12. Blephasteam instructions for use.